HK1021142A1 - Combined vaccines comprising hepatitis b surface antigen and other antigens - Google Patents

Combined vaccines comprising hepatitis b surface antigen and other antigens

Info

Publication number
HK1021142A1
HK1021142A1 HK00100138.3A HK00100138A HK1021142A1 HK 1021142 A1 HK1021142 A1 HK 1021142A1 HK 00100138 A HK00100138 A HK 00100138A HK 1021142 A1 HK1021142 A1 HK 1021142A1
Authority
HK
Hong Kong
Prior art keywords
hepatitis
antigens
surface antigen
combined vaccines
vaccines
Prior art date
Application number
HK00100138.3A
Other languages
English (en)
Inventor
Jean Petre
Pierre Hauser
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26300928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1021142(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB929211081A external-priority patent/GB9211081D0/en
Priority claimed from GB929213308A external-priority patent/GB9213308D0/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of HK1021142A1 publication Critical patent/HK1021142A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
HK00100138.3A 1992-05-23 1998-11-30 Combined vaccines comprising hepatitis b surface antigen and other antigens HK1021142A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929211081A GB9211081D0 (en) 1992-05-23 1992-05-23 Vaccines
GB929213308A GB9213308D0 (en) 1992-06-23 1992-06-23 Vaccine
HK98112444A HK1011290A1 (en) 1992-05-23 1998-11-30 Combined vaccines comprising hepatitis b surface antigen and other antigens

Publications (1)

Publication Number Publication Date
HK1021142A1 true HK1021142A1 (en) 2000-06-02

Family

ID=26300928

Family Applications (2)

Application Number Title Priority Date Filing Date
HK00100138.3A HK1021142A1 (en) 1992-05-23 1998-11-30 Combined vaccines comprising hepatitis b surface antigen and other antigens
HK98112444A HK1011290A1 (en) 1992-05-23 1998-11-30 Combined vaccines comprising hepatitis b surface antigen and other antigens

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK98112444A HK1011290A1 (en) 1992-05-23 1998-11-30 Combined vaccines comprising hepatitis b surface antigen and other antigens

Country Status (31)

Country Link
US (1) US6013264A (uk)
EP (4) EP0642355B1 (uk)
JP (1) JP3626996B2 (uk)
KR (1) KR100287083B1 (uk)
CN (2) CN1313152C (uk)
AP (1) AP567A (uk)
AT (2) ATE444079T1 (uk)
AU (5) AU4315693A (uk)
CA (1) CA2136429C (uk)
CY (1) CY2614B2 (uk)
CZ (1) CZ283910B6 (uk)
DE (4) DE122010000015I1 (uk)
DK (2) DK0835663T3 (uk)
ES (2) ES2118963T3 (uk)
FI (1) FI945483A (uk)
HK (2) HK1021142A1 (uk)
HU (1) HU220236B (uk)
IL (1) IL105770A (uk)
LU (2) LU91658I2 (uk)
MA (1) MA22894A1 (uk)
MX (1) MX9302982A (uk)
MY (1) MY110665A (uk)
NO (1) NO309675B1 (uk)
NZ (1) NZ253065A (uk)
PT (1) PT835663E (uk)
RU (1) RU2160120C2 (uk)
SG (1) SG48365A1 (uk)
SI (1) SI9300271A (uk)
SK (1) SK280702B6 (uk)
UA (1) UA40596C2 (uk)
WO (1) WO1993024148A1 (uk)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9503863D0 (en) * 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
US6696065B1 (en) 1995-05-04 2004-02-24 Aventis Pastuer Limited Acellular pertussis vaccines and methods of preparation thereof
FR2734484B1 (fr) * 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US20020054884A1 (en) 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
EP0833662B2 (en) 1995-06-23 2011-01-26 SmithKline Beecham Biologicals S.A. A vaccine composition comprsing a Haemophilus influenzae B polysaccharide conjugate antigen adsorbed onto aluminium phosphate
BRPI9710460B8 (pt) * 1996-07-02 2021-05-25 Aventis Pasteur composição imunogênica multi-valente e composição de vacina
US20010014331A1 (en) 1996-11-07 2001-08-16 Smithkline Beecham Biologicals S.A. Acellular pertussis vaccine with diphthriae-and tetanus-toxoids
GB9623233D0 (en) 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
CU22629A1 (es) * 1997-03-06 2000-12-22 Ct Ingenieria Genetica Biotech Formulaciones inmunopotenciadoras para uso vacunal
AU750702B2 (en) * 1997-05-01 2002-07-25 Chiron Corporation Use of virus-like particles as adjuvants
AU4707097A (en) * 1997-09-15 1999-04-05 Pasteur Merieux Serums Et Vaccins Multivalent vaccines
IL137998A0 (en) * 1998-03-09 2001-10-31 Smithkline Beecham Biolog Combined vaccine compositions
GB9806456D0 (en) * 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
GB9809507D0 (en) * 1998-05-01 1998-07-01 Smithkline Beecham Biolog Novel composition
US20030049268A1 (en) 1998-05-01 2003-03-13 Smithkline Beecham Biologicals S.A. Novel composition
RU2130778C1 (ru) * 1998-07-31 1999-05-27 Акционерное общество закрытого типа НПК "Комбиотех Лтд" Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка, дифтерии и коклюша
RU2130779C1 (ru) * 1998-07-31 1999-05-27 Акционерное общество закрытого типа Научно-производственная компания "Комбиотех Лтд" Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка и дифтерии
AT408615B (de) * 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
EP1126876B1 (en) 1998-10-16 2007-03-21 GlaxoSmithKline Biologicals S.A. Adjuvant systems and vaccines
CN1053590C (zh) * 1998-10-19 2000-06-21 卫生部长春生物制品研究所 冻干甲型肝炎减毒活疫苗及其保护剂
CU22871A1 (es) * 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
US6974581B1 (en) * 1998-12-15 2005-12-13 Aventis Pasteur Limited Multi-component vaccine comprising at least two antigens from haemophilus influenzae to protect against disease
US7098309B2 (en) * 1998-12-23 2006-08-29 Merck & Co., Inc. Recombinant hepatitis B surface antigen
US7172762B1 (en) * 1999-01-29 2007-02-06 Pfizer Inc. Erysipelothrix rhusiopathiae antigens and vaccine compositions
GB9923060D0 (en) 1999-09-29 1999-12-01 Chiron Spa Vaccine
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
KR100374813B1 (ko) * 2000-04-07 2003-03-03 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드, 정제백일해 및비형간염표면항원을 포함한 4가 혼합백신 및 그 제조 방법
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
JP4870895B2 (ja) 2000-06-29 2012-02-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン組成物
KR100385711B1 (ko) * 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
KR100401423B1 (ko) * 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
JP2005504718A (ja) 2001-01-23 2005-02-17 アヴェンティス パストゥール 多価髄膜炎菌多糖−タンパク質複合ワクチン
AU2007200116A1 (en) * 2001-04-03 2007-02-01 Glaxosmithkline Biologicals S.A. Vaccine composition
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
WO2003009869A1 (en) * 2001-07-26 2003-02-06 Chiron Srl. Vaccines comprising aluminium adjuvants and histidine
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
CU23031A1 (es) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
US20050129712A1 (en) * 2002-03-28 2005-06-16 Hansjorg Reimann Combined dna/protein vaccine compositions
GB0223355D0 (en) * 2002-10-08 2002-11-13 Chiron Spa Vaccine
US8409587B2 (en) 2002-11-01 2013-04-02 Glaxosmithkline Biologicals S.A. Immunogenic composition
CN102302776B (zh) 2003-01-30 2014-06-18 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
BRPI0415025A (pt) 2003-10-02 2006-12-12 Chiron Srl vacinas lìquidas para sorogrupos meningocócicos múltiplos
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
CN1984679B (zh) 2004-06-04 2013-05-15 美国政府健康及人类服务部 制备免疫原性结合物的方法
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
SG175456A1 (en) 2005-04-18 2011-11-28 Novartis Vaccines & Diagnostic Expressing hepatitis b virus surface antigen for vaccine preparation
US8329184B2 (en) 2005-06-27 2012-12-11 Glaxosmithkline Biologicals S.A. Process for manufacturing vaccines
GB0517719D0 (en) * 2005-08-31 2005-10-05 Chiron Srl Vaccines containing pili
CA2621023C (en) 2005-09-01 2019-07-02 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Multiple vaccination including serogroup c meningococcus
GB0522765D0 (en) * 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
EP1862176A1 (de) * 2006-05-31 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Ein Verfahren zur Herstellung einer Impfzusammensetzung
EP1862177A1 (de) * 2006-06-01 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Ein Verfahren zur Herstellung einer Impfzusammensetzung
GB0616226D0 (en) * 2006-08-15 2006-09-27 Novartis Ag Processes
GB0616306D0 (en) * 2006-08-16 2006-09-27 Novartis Ag Vaccines
GB0617602D0 (en) * 2006-09-07 2006-10-18 Glaxosmithkline Biolog Sa Vaccine
EA016417B1 (ru) 2006-09-07 2012-04-30 Глаксосмитклайн Байолоджикалс С.А. Способ получения вакцины
WO2008095677A1 (en) * 2007-02-07 2008-08-14 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Recombinant antigens of human cytomegalovirus (hcmv)
AR066376A1 (es) 2007-05-02 2009-08-12 Glaxosmithkline Biolog Sa Vacuna
PE20100366A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
PE20100365A1 (es) 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
IT1398927B1 (it) 2009-06-25 2013-03-28 Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
FR2966044B1 (fr) 2010-10-18 2012-11-02 Sanofi Pasteur Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium
EA025152B1 (ru) 2010-12-02 2016-11-30 Бионор Иммуно Ас Конструкция пептидного каркаса
RU2013136397A (ru) 2011-01-05 2015-02-10 Бхарат Байотек Интернэшнл Лимитед Комбинированная семивалентная вакцина
AU2012204955B2 (en) 2011-01-06 2016-10-06 Bionor Immuno As Monomeric and multimeric immunogenic peptides
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
KR20140066126A (ko) * 2011-05-11 2014-05-30 리스벡 헬스케어 스웨덴 에이비 단백질 f - 라미닌 및 비트로넥틴 결합 특성을 갖는 신규한 헤모필러스 인플루엔자 부착분자
US20140234360A1 (en) 2011-09-30 2014-08-21 The United States of America, as represented by the Secretary, Dept.of Health and Human Services Influenza vaccine
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
FR2985663B1 (fr) * 2012-01-17 2015-03-27 Sanofi Pasteur Procede de formulation d'un vaccin contenant au moins deux antigenes susceptibles de s'adsorber sur de l'oxy hydroxyde d'aluminium
PT2809343T (pt) 2012-02-01 2017-12-21 Glaxosmithkline Biologicals Sa Processo de fermentação
JP2015509963A (ja) * 2012-03-08 2015-04-02 ノバルティス アーゲー Ｔｌｒ４アゴニストを含む混合ワクチン
KR20150018870A (ko) 2012-06-06 2015-02-24 바이오노르 이뮤노 에이에스 면역원 및 투여 반응제로서 사용하기 위한 바이러스 단백질로부터 유래하는 펩타이드
CA2879939A1 (en) 2012-08-06 2014-02-13 Glaxosmithkline Biologicals S.A. Novel method
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
CA2886938A1 (en) 2012-10-12 2014-04-17 Glaxosmithkline Biologicals S.A. Non-cross-linked acellular pertussis antigens for use in combination vaccines
WO2014135651A1 (en) 2013-03-08 2014-09-12 Crucell Holland B.V. Acellular pertussis vaccine
WO2014164727A1 (en) 2013-03-12 2014-10-09 Wisconsin Alumni Research Foundation A method of treating fungal infection
SG11201600709TA (en) 2013-08-05 2016-02-26 Glaxosmithkline Biolog Sa Combination immunogenic compositions
WO2016012385A1 (en) 2014-07-21 2016-01-28 Sanofi Pasteur Vaccine composition comprising ipv and cyclodextrins
WO2017048038A1 (en) * 2015-09-16 2017-03-23 Lg Life Sciences Ltd. Combination vaccine composition for multiple-dosage
EP3518968B1 (en) 2016-10-03 2022-01-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Hiv-1 env fusion peptide immunogens and their use
US11202824B2 (en) 2016-10-31 2021-12-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide fragments from filoviruses and their uses
WO2018176031A1 (en) 2017-03-24 2018-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Glycan-masked engineered outer domains of hiv-1 gp120 and their use
EA202090316A1 (ru) 2017-07-18 2020-12-08 Серум Инститьют Оф Индия Пвт Лтд. Иммуногенная композиция с повышенной стабильностью, усиленной иммуногенностью и уменьшенной реактогенностью и способ ее получения
WO2019079337A1 (en) 2017-10-16 2019-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE
WO2020043874A1 (en) 2018-08-31 2020-03-05 Glaxosmithkline Biologicals Sa Conjugated haemophilus influenzae vaccine using bordetella outer membrane vesicle
US20210353740A1 (en) 2018-09-23 2021-11-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Hiv-1 env fusion peptide nanoparticle carrier conjugates and their use
JOP20190242A1 (ar) 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
EP3870703A1 (en) 2018-10-22 2021-09-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Recombinant gp120 protein with v1-loop deletion
US11433129B2 (en) 2019-05-20 2022-09-06 Soligenix, Inc. Compositions and methods of manufacturing trivalent filovirus vaccines
US20230109142A1 (en) 2020-02-14 2023-04-06 Immunor As Corona virus vaccine
WO2021176409A1 (en) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Preservative combination for vaccine composition
KR20230173114A (ko) * 2021-04-20 2023-12-26 케이엠 바이올로직스 가부시키가이샤 6종 혼합 액상 백신 조성물
WO2023015186A1 (en) 2021-08-03 2023-02-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists
WO2023192835A1 (en) 2022-03-27 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Base-covered hiv-1 envelope ectodomains and their use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6013718A (ja) * 1983-07-05 1985-01-24 Chemo Sero Therapeut Res Inst Ｂ型肝炎ワクチン
JPS60193925A (ja) * 1984-03-13 1985-10-02 Chemo Sero Therapeut Res Inst 凍結乾燥製剤化ワクチン
US4624918A (en) * 1984-07-09 1986-11-25 Genentech, Inc. Purification process for hepatitis surface antigen and product thereof
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
AP56A (en) 1987-01-30 1989-09-26 Smithkline Biologicals S A Hepatitis B virus surface antigens and hybrid antigehs containing them.
EP0304578B1 (en) 1987-06-22 2001-10-24 Medeva Holdings Bv Peptide comprising hepatitis B surface antigen
EP0299108B1 (en) 1987-07-17 1994-05-18 Rhein Biotech Gesellschaft für biotechnologische Prozesse und Produkte mbH DNA-molecules coding for FMDH control regions and structured gene for a protein having FMDH-activity and their uses
JPH085804B2 (ja) 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン
ATE159031T1 (de) 1989-07-25 1997-10-15 Smithkline Biolog Antigene sowie verfahren zu deren herstellung
DK0427462T3 (da) 1989-11-06 1996-03-11 Smithkline Beecham Biolog Fremgangsmåde
CA2075711C (en) 1990-02-12 2000-11-07 Carine Capiau Vaccine and method therefor
GB9007024D0 (en) 1990-03-29 1990-05-30 Imperial College Novel vaccine
EP0563091A1 (en) * 1990-12-20 1993-10-06 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccines based on hepatitis b surface antigen
CA2067003A1 (en) 1991-04-29 1992-10-30 Peter J. Kniskern Hbsag escape mutant vaccine
WO1993005811A1 (en) * 1991-09-18 1993-04-01 Amgen Inc. A hepatitis b vaccine formulation incorporating a bile acid salt
ES2162139T5 (es) * 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
EP0833662B2 (en) 1995-06-23 2011-01-26 SmithKline Beecham Biologicals S.A. A vaccine composition comprsing a Haemophilus influenzae B polysaccharide conjugate antigen adsorbed onto aluminium phosphate
RU2130778C1 (ru) 1998-07-31 1999-05-27 Акционерное общество закрытого типа НПК "Комбиотех Лтд" Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка, дифтерии и коклюша
KR100385711B1 (ko) 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
KR100401423B1 (ko) 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법

Also Published As

Publication number Publication date
RU94046145A (ru) 1997-03-27
AU5062902A (en) 2002-08-08
CA2136429C (en) 2001-12-11
EP0642355B1 (en) 1998-07-15
CN1313152C (zh) 2007-05-02
FI945483A (fi) 1995-01-20
AU4315693A (en) 1993-12-30
SK142194A3 (en) 1995-08-09
NZ253065A (en) 1996-10-28
US6013264A (en) 2000-01-11
LU91658I2 (fr) 2010-05-03
JP3626996B2 (ja) 2005-03-09
KR100287083B1 (ko) 2001-04-16
CN1136918C (zh) 2004-02-04
MA22894A1 (fr) 1993-12-31
AU2007201162A1 (en) 2007-04-19
CZ283910B6 (cs) 1998-07-15
AP567A (en) 1996-11-25
ATE444079T1 (de) 2009-10-15
ATE168271T1 (de) 1998-08-15
KR950701822A (ko) 1995-05-17
NO309675B1 (no) 2001-03-12
AU1648097A (en) 1997-05-29
EP2289548A3 (en) 2012-08-08
SK280702B6 (sk) 2000-06-12
EP2289548A2 (en) 2011-03-02
DK0642355T3 (da) 1998-11-30
EP0642355A1 (en) 1995-03-15
AU2010200249A1 (en) 2010-02-11
CZ289294A3 (en) 1995-09-13
WO1993024148A1 (en) 1993-12-09
PT835663E (pt) 2010-01-04
SG48365A1 (en) 1998-04-17
EP0835663A2 (en) 1998-04-15
DK0835663T3 (da) 2010-02-01
NO944475L (no) 1995-01-18
JPH07508267A (ja) 1995-09-14
UA40596C2 (uk) 2001-08-15
CY2614B2 (en) 2012-01-25
FI945483A0 (fi) 1994-11-22
MY110665A (en) 1999-01-30
SI9300271A (en) 1993-12-31
AU709406B2 (en) 1999-08-26
DE122010000016I1 (de) 2010-07-08
CA2136429A1 (en) 1993-12-09
IL105770A0 (en) 1993-09-22
IL105770A (en) 1998-08-16
CN1623602A (zh) 2005-06-08
HU220236B (hu) 2001-11-28
HU9403366D0 (en) 1995-02-28
ES2118963T3 (es) 1998-10-01
DE69334297D1 (de) 2009-11-12
EP0835663A3 (en) 1999-03-03
DE69319728D1 (de) 1998-08-20
DE69319728T2 (de) 1999-02-04
AU709406C (en) 2004-04-08
EP2156845A1 (en) 2010-02-24
MX9302982A (es) 1993-12-01
AU785433B2 (en) 2007-05-31
HUT71791A (en) 1996-02-28
ES2334181T3 (es) 2010-03-05
LU91659I2 (fr) 2010-05-03
EP0835663B1 (en) 2009-09-30
NO944475D0 (no) 1994-11-22
HK1011290A1 (en) 1999-07-09
AU2010200249B2 (en) 2012-01-12
RU2160120C2 (ru) 2000-12-10
AP9300530A0 (en) 1993-07-31
DE122010000015I1 (de) 2010-07-08
CN1085450A (zh) 1994-04-20

Similar Documents

Publication Publication Date Title
HK1021142A1 (en) Combined vaccines comprising hepatitis b surface antigen and other antigens
AU9052091A (en) Vaccines based on hepatitis b surface antigen
ZA88488B (en) Hepatitis b virus surface antigens and hybrid antigens containing them
GB9324607D0 (en) Hepatitis c diagnostics and vaccines
IL81920A (en) Vaccines comprising an antigen and interferon-ypsilon and their preparation
NZ224862A (en) Taenia ovis antigens and vaccines
EP0542753A4 (en) Epitopes of the pre-s region of hepatitis b virus surface antigen
GB2238959B (en) Antigen and conjugates thereof for suppressing immune response
IL104291A0 (en) Antigenic epitopes and antibodies against them
AU6769594A (en) Hepatitis c virus immunodiagnostic antigens and antibodies
GB9021286D0 (en) Antigens and antibodies thereto their uses
AU3269793A (en) Method for obtaining recombinant surface antigen of hepatitis B, antigen and vaccine based on it
ZA932210B (en) A process for preparation of a recombinant hepatitis B surface antigen, and antigen and vaccine based thereon
AU3931197A (en) Vaccines and antigenic conjugates
IL104767A0 (en) Antigenic epitopes and antibodies against them
GB8828523D0 (en) St-lt recombinant antigen vaccines
ZA924950B (en) Hcv peptide antigens and methods for the determination of hcv
IE871644L (en) T and b cell epitopes of the pre-s region of hepatitis b¹virus surface antigen
GB9212816D0 (en) Vaccines and their uses
BR1100913A (pt) Vacinas combinadas compreendendo o antìgeno superficial da hepatite b e outros antìgenos
IE880458L (en) Virus antigen

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20130514